Charles L Sawyer

US Patent:

20070166717, Jul 19, 2007

Filed:

Dec 16, 2004

Appl. No.:

10/583280

Inventors:

Charles Sawyer - Los Angeles CA, US
Charlie Chen - Los Angeles CA, US
Derek Welsbie - Northridge CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

C12Q 1/68
A61K 48/00

US Classification:

435006000, 514044000

Abstract:

Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.

US Patent:

6107540, Aug 22, 2000

Filed:

Oct 15, 1997

Appl. No.:

8/951143

Inventors:

Charles L. Sawyer - Los Angeles CA
Karen A. Klein - Los Angeles CA
Owen N. Witte - Sherman Oaks CA
Robert E. Reiter - Los Angeles CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 500
C12N 1500
A61K 4900
G01N 3100

US Classification:

800 10

Abstract:

The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.